Independent research on the U.S. markets, Baptista Research

Baptista Research

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. 

We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Teva Pharmaceutical Sp Adr / Equity Bottom-Up

<ul><li>Teva Pharmaceutical Industries Limited reported first-quarter 2026 results reflecting ongoing progress in its strategic transformation from a primarily generics-focused company to a diversified biopharmaceutical firm.</li><li>The company continues to advance its “Pivot to Growth” strategy, which emphasizes four core pillars: growth through innovative products, increased innovation, sustaining generics leadership with an emerging biosimilar portfolio, and focusing the business on high-return areas.</li><li>First-quarter revenues amounted to approximately $4 billion, representing a 1% decline in local currency but a 7% increase when excluding the divestment of its Japan business and the loss of generic REVLIMID revenues, which was expected.</li></ul>

Teva Pharmaceutical Industries Limited reported first-quarter 2026 results reflecting ongoing progress in its strategic transformation from a primarily generics-focused company to a diversified biopharmaceutical firm.The company continues to advance its “Pivot to Growth” strategy, which emphasizes four core pillars: growth through innovative products, increased innovation, sustaining generics leadership with an emerging biosimilar portfolio, and focusing the business on high-return areas.First-quarter revenues amounted to approximately $4 billion, representing a 1% decline in local currency but a 7% increase when excluding the divestment of its Japan business and the loss of generic REVLIMID revenues, which was expected.

Teva Pharmaceutical: Initiation Of Coverage